论文部分内容阅读
目的 :探讨康莱特注射液辅助治疗对肝癌介入术后患者生活质量及免疫功能的影响。方法 :76例肝癌介入治疗后住院患者随机分为治疗组和对照组各 38例 ,对照组予一般支持和对症治疗 ,治疗组予康莱特 2 0 0mL每日静脉滴注 1次 ,2 1日为 1疗程。观察治疗前后临床症状、生活质量评分、免疫功能的变化及不良反应。结果 :治疗组治疗后临床症状改善率 (肝区痛改善有效率 6 1%、腹胀 5 3%、乏力 70 % )优于对照组 (分别为 4 3%、 37%、 5 1% ) ,均为P <0 0 1;治疗组生活质量评分提高 2 3例(6 1% ) ,对照组为 12例 (32 % ) ,P <0 0 1;治疗组治疗后T细胞分化群 (clusterofdifferentiation ,CD) 3、CD4、T细胞转化率均明显提高 [分别为 (6 1± 4 ) %、 (4 1± 4 ) %、 (6 1± 11) % ],优于对照组 [分别为(5 0± 5 ) %、 (30± 4 ) %、 (4 8± 3) % ],P <0 0 1,P <0 0 5 ,P <0 0 5。结论 :康莱特注射液辅助治疗能明显提高肝癌介入术后患者的生活质量及免疫功能 ,从而有效提高晚期肝癌患者的综合治疗效果。
Objective: To investigate the effect of Kanglaite injection adjuvant therapy on quality of life and immune function in patients with liver cancer after interventional therapy. Methods: A total of 76 hospitalized patients with hepatocellular carcinoma after interventional therapy were randomly divided into treatment group and control group, with 38 cases in each group. The control group received general support and symptomatic treatment. The treatment group received Kanglaite 200 ml daily intravenous drip once, For a course of treatment. Clinical symptoms before and after treatment, quality of life scores, changes in immune function and adverse reactions were observed. Results: The improvement rate of clinical symptoms (effective rate of liver area pain was 61%, abdominal distension 53%, fatigue 70%) was better than that of the control group (43%, 37%, 51% respectively) after treatment (P <0.01). The quality of life scores of the treatment group increased by 23% (61%) compared with 12 cases (32%) in the control group, P <0.01. The cluster of differentiation (CD ) Were significantly higher than those in the control group [(50%, respectively; (4 1 ± 4)%, (6 1 ± 11)%] ± 5%, (30 ± 4)%, (48 ± 3)%], P <0 01, P 0 05, P 0 05, respectively. Conclusion: Kanglaite injection adjuvant therapy can significantly improve the quality of life and immune function in patients with liver cancer after interventional therapy, thereby effectively increasing the comprehensive treatment of patients with advanced liver cancer.